UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 23, 2023

GE HEALTHCARE TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

	001-41528	88-2515116
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
500 W. Monroe Street Chicago, IL		60661
(Address of principal executive offices)		(Zip Code)
(Registrant's telep	ohone number, including area code) (833 <u>)</u> 735-1139
(Former name	e or former address, if changed since I	last report.)
	ed to simultaneously satisfy the filing o	obligation of the registrant under any of the following
erial pursuant to Rule 14a-12 under the Exch ement communications pursuant to Rule 14	ange Act (17 CFR 240.14a-12) d-2(b) under the Exchange Act (17 CFI	· //
ed pursuant to Section 12(b) of the Act:		
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
stock, par value \$0.01 per share	G EH C	The Nasdaq Stock Market LLC
ck mark whether the registrant is an emergin e 12b-2 of the Securities Exchange Act of 193	ng growth company as defined in Rule 34 (§ 240.12b-2 of this chapter).	405 of the Securities Act of 1933 (§230.405 of this
		Emerging growth company □
	(Address of principal executive offices) (Registrant's tele) (Former name) ate box below if the Form 8-K filing is intendeneral Instructions A2. below): unications pursuant to Rule 425 under the Scenial pursuant to Rule 14a-12 under the Exchement communications pursuant to Rule 14 exement communications pursuant to Rule 13 exemptions are successful.	(Address of principal executive offices) (Registrant's telephone number, including area code) (Former name or former address, if changed since atte box below if the Form 8-K filing is intended to simultaneously satisfy the filing coneral Instructions A2. below): unications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) erial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14a-12) exement communications pursuant to Rule 13e-4(c) under the Exchange Ac

Item 5.07 Submission of Matters to a Vote of Security Holders.

GE HealthCare Technologies Inc. ("GE HealthCare," "we," or "our") held our annual meeting of stockholders on May 23, 2023 (the "Annual Meeting"). As of March 27, 2023, the record date for the meeting, 454,608,434 shares of our common stock were issued and outstanding. A quorum of 398,069,569 shares of common stock was present or represented at the meeting. Set forth below are the final voting results for each of the matters submitted to a vote of the stockholders. For more information about the proposals set forth below, please see our definitive proxy statement filed with the Securities and Exchange Commission on April 5, 2023.

1. Our stockholders elected 10 directors to each serve a one-year term until our 2024 annual meeting of stockholders or until his or her successor has been elected and qualified, based on the following voting results:

Nominee	Votes For	Votes Against	Abstentions	Broker Non-Votes
Peter J. Arduini	357,184,541	1,199,832	442,412	39,242,784
H. Lawrence Culp, Jr.	346,524,762	11,475,042	826,981	39,242,784
Rodney F. Hochman	357,104,309	1,247,299	475,177	39,242,784
Lloyd W. Howell, Jr.	357,036,663	1,266,776	523,346	39,242,784
Risa Lavizzo-Mourey	340,567,532	17,831,016	428,237	39,242,784
Catherine Lesjak	356,542,047	1,806,049	478,689	39,242,784
Anne T. Madden	357,179,125	1,223,196	424,464	39,242,784
Tomislav Mihaljevic	357,038,730	1,318,611	469,444	39,242,784
William J. Stromberg	357,050,178	1,250,337	526,270	39,242,784
Phoebe L. Yang	357,008,665	1,331,444	486,676	39,242,784

2. Our stockholders approved our named executive officers' compensation in an advisory vote, based on the following voting results:

Votes For		Votes Against	Abstentions	Broker Non-Votes	
	346.918.208	10.525.315	1.383.262	39.242.784	

Our stockholders approved one year as the frequency of future advisory votes on our named executive officers' compensation in an advisory vote, based on the following voting results:

_	1 Year	Year 2 Years		Abstentions	
	353.577.972	537.687	3.969.878	741.248	

Based on the results above, and consistent with the recommendation of the Board of Directors of GE HealthCare (the "Board"), the Board has determined that future advisory votes on executive compensation will be submitted to stockholders on an annual basis until the next required vote on the frequency of such votes.

4. Our stockholders ratified the appointment of Deloitte & Touche LLP as our independent auditor for the fiscal year ending December 31, 2023, based on the following voting results:

Votes For	Votes Against	Abstentions	Broker Non-Votes	
396,057,400	1,517,934	494,235	_	

SIGNATURES

Pursuant to the requirement	ents of the Securities	Exchange Act of 1934	, the registrant has du	uly caused this r	eport to be signed	on its behalf by the
undersigned hereunto duly	y authorized.					

GE HealthCare Technologies Inc.
(Registrant)

Date: May 25, 2023 /s/ Frank R. Jimenez

Frank R. Jimenez, General Counsel and Corporate Secretary (authorized signatory)